Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of radium-223 plus abiraterone and prednisone/prednisolone in chemotherapy-naive bone-predominant metastatic castration-resistant prostate cancer
2013-003438-33Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of radium-223 dichloride, abiraterone, prednisone and prednisolone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Bayer. Primary endpoint: Symptomatic skeletal event-free survival. Started Jan 2014; status: completed.
02
Drugs
radium-223 dichlorideabirateroneprednisoneprednisolone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-003438-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003438-33.